DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity

Vaccine

Volumn 15, Issue 10, 1997, Pages 1049-1056

  Okuda, Kenji ^a   Xin, Ke Qin ^a   Tsuji, Takashi ^a   Bukawa, Hiroki ^a   Tanaka, Shun Ichi ^a   Koff, Wayne C ^b   Tani, Kenji ^a   Okuda, Katsuji ^c   Honma, Kiyonobu ^c   Kawamoto, Susumu ^a   Hamajima, Kenji ^a   Fukushima, Jun ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b United Biomedical Inc   (United States)

^c Tokyo Denki University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; GUINEA PIGS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-4; MACACA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RABBITS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, DNA;

EID: 18544393999     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00045-5     Document Type: Article

References (47)

1. Cease, B., Margalit, H. and Cornette, J.L. et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc. Natl Acad. Sci. U.S.A. 1987, 84, 4249-4253.
2. Goudsmit, J. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl Acad. Sci. U.S.A 1988, 85, 4478-4482.
3. Ho, D.D. and Kaplan, J.C. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 1988, 239, 1021-1023.
4. Koff, W.C. and Hoth, D.F. Development and testing of AIDS vaccines. Science 1988, 241, 426-432.
5. Ada, G. Prospects for a vaccine against HIV. Nature 1989, 339, 331-332.
6. Bolognesi, D.P. Prospects for prevention of and early intervention against HIV. J. Am. Med. Assoc. 1989, 261, 3007-3013.
7. Achour, A., Picard, O. and Zagury, D. et al. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc. Natl Acad. Sci. U.S.A. 1990, 87, 7045-7049.
8. Okuda, K., Bukawa, H. and Hamajima, K. et al. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the type 1 env and rev gene products. AIDS Res. Hum. Retroviruses 1995, 11, 933-943.
9. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. and Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258, 1938-1941.
10. Langlade-Demoyen, P., Ngo-Giang-Huong, N., Ferchal, F. and Oksenhendler, E. HIV nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. Clin. Invest. 1994, 93, 1293-1297.
11. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344, 873-875.
12. mac251 gag and env vaccines containing QS-21 saponin adjuvant. AIDS Res. Hum. Retroviruses 1994, 10, 853-861.
13. Salk, J., Bretscher, P.A., Salk, P.L., Clerici, G. and Sheare, A. Strategy for prophylactic vaccination against HIV. Science 1993, 260, 1270-1271.
14. Clerici, M. and Shearer, G.M. The Th1-Th2 hypotheses of HIV infection: new insights. Immunol. Today 1984, 15, 575-581.
15. Bukawa, H., Sekigawa, K.-I. and Hamajima, K. et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med. 1995, 1, 681-685.
16. Bukawa, H., Fukushima, J. and Hamajima, K. et al. Antibody responses raised against a conformational V3 loop peptide of HIV-1. Microbiol. Immunol. 1995, 39, 607-614.
17. Okuda, K., Bukawa, H. and Kawamoto, S. et al. A serologic analysis and amino acid sequence of the V3 region of human immunodeficiency virus from carriers in Bangkok. J. Infect. Dis. 1994, 169, 227-228.
18. Ubolyam, U., Ruxrungtham, K., Sirivichayakul, S., Okuda, K. and Phanuphak, P. Evidence of three HIV-1 subtypes in subgroups of individuals in Thailand. Lancet 1994, 344, 484-485.
19. McKeating, J.A., Cordell, J., Dean, C.J. and Balfe, P. Synergistic interaction between ligands to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 1992, 191, 732-742.
20. Girard, M., Kieny, M.P. and Pinter, A. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. U.S.A. 1991, 88, 542-546.
21. Fultz, P.N., Nara, P. and Barre-Sinoussi, F. et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256, 1687-1690.
22. Shimizu, N., Takeuchi, Y. and Naruse, T. et al. Six strains of human immunodeficiency virus type 1 isolated in Japan and their molecular phylogeny. J. Mol. Evol. 1992, 35, 329-336.
23. Xin, K.-Q., Ma, X.-H., Crandall, K.A., Bukawa, H., Kawamoto, S. and Okuda, K. Evidence of dual infection of HIV-1 typical subtypes B and E in a Thai individual. Lancet 1995, 346, 1372-1373.
24. Koga, Y., Sasaki, H., Yoshida, H., Wigzell, G., Kimura, G. and Nomoto, K. Cytopathic effect determined by the amount of CD4 molecules in human cell lines expressing envelope glycoprotein of HIV. J. Immunol. 1990, 144, 94-102.
25. Cullen, B.R. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 1986, 46, 973-982.
26. Malim, M.H., Hauber, J., Fenrick, R. and Cullen, B.R. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 1988, 335, 181-183.
27. Inami, S., Taniguchi, N. and Ishibashi, K. et al. Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1 infected individuals. AIDS 1991, 5, 1140-1141.
28. Okuda, K., Kaneko, T. and Yamakawa, T. et al. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection. J. Clin. Lab. Immunol. 1993, 40, 97-113.
29. Okuda, K., Kaneko, T. and Yamakawa, T. et al. Strong immunogenicity of a multicomponent vaccine developed with the branched lysine oligopeptide (BLO) method for human immunodeficiency virus-1 (HIV-1) infection. J. Mol. Recognition 1993, 6, 101-109.
30. Clerici, M., Lucey, D.R. and Zajac, R.A. et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individual. J. Immunol. 1991, 146, 2214-2219.
31. Yamamoto, H., Miller, M.D. and Tsubota, H. et al. Studies of cloned simian immunodeficiency virus-specific T lymphocytes. J. Immunol. 1990, 144, 3385-3391.
32. Shirai, A., Sierra, V., Kelly, C.I. and Klinman, D. Individual cells simultaneously produce both IL-4 and IL-6 in vivo. Cytokine 1994, 6, 329-336.
33. +T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J. Exp. Med. 1992, 176, 1335-1341.
34. ds:Sequence motif, quantitative binding, and molecular modeling of the complex. J. Exp. Med. 1992, 176, 1681-1692.
35. Walker, C.M., Moody, D.J., Stites, D.P. and Levy, J.A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 334, 1563-1566.
36. Clerici, M., Giorge, J.V. and Chore, C.-C. et al. Cell mediated immune response to human immunodeficiency virus (HIV) type-1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 1992, 165, 1012-1019.
37. Carmichael, A., Jin, X., Sissons, P. and Borysiewicz, L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 1993, 177, 249-256.
38. Bohm, W., Schirmbeck, R. and Elbe, A. et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J. Immunol. 1995, 155, 3313-3321.
39. Xiang, Z.Q., Spitalnic, S., Tran, M., Wunner, W.H., Cheng, J. and Ertl, H.C.J. Vaccination with a plasmid carrying the rabies glycoprotein gene induces protective immunity against rabies virus. Virology 1994, 199, 132-140.
40. Ulmer, J.B., Donnelly, J.J. and Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
41. Davis, H.L., Michel, M.L., Mancini, M., Schleef, M. and Whalen, R.G. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 1994, 12, 1503-1509.
42. Tascon, R.E., Colston, M.J., Ragno, S., Stavropoulos, E., Gregory, D. and Lowrie, D.B. Vaccination against tuberculosis by DNA injection. Nature Med. 1996, 2, 888-892.
43. Huygen, K., Content, J. and Denis, O. et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med. 1996, 2, 893-898.
44. Dennelly, J.J., Friedman, A. and Martines, D. et al. Preclinical efficacy of a protype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Med. 1995, 1, 583-587.
45. Cooney, E.L., McElrath, M.J. and Corey, L. et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. U.S.A. 1993, 90, 1882-1886.
46. Cox, W.I., Tartaglia, J. and Paoletti, E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NY-VAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993, 195, 845-850.
47. MN env gene. J. Infect. Dis. 1995, 171, 1623-1627.